FDA approves PharmaEssentia BESREMi for adults with essential thrombocythemia

• FDA cleared PharmaEssentia’s BESREMi for adults with essential thrombocythemia, the first new US-approved ET therapy in nearly 30 years.
• Label covers all adult ET patients regardless of genotype or disease status, including newly diagnosed patients who have not used cytoreductive therapy.
• Decision relied on Phase 3 SURPASS ET data showing superior durable responses versus anagrelide, with fewer thromboembolic events over 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaEssentia Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202608310800BIZWIRE_USPR_____20260831_BW907028) on August 31, 2026, and is solely responsible for the information contained therein.